Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes
- 20 July 2016
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 27 (12) , 3637-3643
Abstract
Summary Two strains of mice with distinct bone morphologies and mechanical properties were treated with zoledronate. Our results show a different response to drug treatment in the two strains providing evidence that baseline properties of structure/material may influence response to zoledronate. Introduction Bisphosphonates are highly effective in reducing fracture risk, yet some individuals treated with these agents still experience fracture. The goal of this study was to test the hypothesis that genotype influences the effect of zoledronate on bone mechanical properties. Methods Skeletally mature male mice from genetic backgrounds known to have distinct baseline post-yield properties (C57/B6, high post-yield displacement; A/J, low post-yield displacement) were treated for 8 weeks with saline (VEH) or zoledronate (ZOL, 0.06 mg/kg subcutaneously once every 4 weeks) in a 2 × 2 study design. Ex vivo μCT and mechanical testing (4-pt bending) were conducted on the femur to assess morphological and mechanical differences. Results Significant drug and/or genotype effects were found for several mechanical properties and significant drug × genotype interactions were found for measures of strength (ultimate force) and brittleness (total displacement, strain to failure). Treatment with ZOL affected bone biomechanical measures of brittleness (total displacement (−25 %) and strain to failure (−23 %)) in B6 mice significantly differently than in A/J mice. This was driven by unique drug × genotype effects on bone geometry in B6 animals yet likely also reflected changes to the tissue properties. Conclusion These data may support the concept that properties of the bone geometry and/or tissue at the time of treatment initiation play a role in determining the bone’s mechanical response to zoledronate treatment.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR62002)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK108554)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR65971)
- National Institutes of Health (OD016208)
This publication has 28 references indexed in Scilit:
- Skeletal Hard Tissue Biomechanics2014
- Biological constraints that limit compensation of a common skeletal trait variant lead to inequivalence of tibial function among healthy young adultsJournal of Bone and Mineral Research, 2011
- Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't knowBone, 2011
- Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandibleOrthodontics & Craniofacial Research, 2010
- Guidelines for assessment of bone microstructure in rodents using micro–computed tomographyJournal of Bone and Mineral Research, 2010
- Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive TreatmentJournal of Bone and Mineral Research, 2008
- Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragilityMammalian Genome, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Genetic Variation in Bone Growth Patterns Defines Adult Mouse Bone FragilityJournal of Bone and Mineral Research, 2005
- Relationship Between Bone Morphology and Bone Quality in Male Tibias: Implications for Stress Fracture RiskJournal of Bone and Mineral Research, 2005